Is OPKO Health, Inc. overvalued or undervalued?

As of 24 February 2022, the valuation grade for OPKO Health, Inc. has moved from attractive to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued based on its current financial metrics, particularly with a Price to Book Value of 0.85 and an EV to Sales ratio of 1.64. Additionally, the EV to EBITDA ratio stands at -6.52, reflecting significant operational challenges.
In comparison to its peers, OPKO Health, Inc. has a notably negative EV to EBITDA ratio of -7.2480, while Hims & Hers Health, Inc. is considered expensive with a P/E ratio of 54.7633, and RadNet, Inc. shows a risky valuation with a P/E of 123.7949. The company's recent stock performance has been lackluster, with a 1-year return of -6.79% compared to the S&P 500's 17.14%, further reinforcing the notion that OPKO Health, Inc. is overvalued in the current market environment.